Skip to main content
. 2023 Mar 4;24(5):4970. doi: 10.3390/ijms24054970

Figure 2.

Figure 2

The first pharmaceutical formulation of deferiprone (L1) in transparent gelatin capsules, which were used for the first clinical trials in London, UK, and also in multicenter clinical trials that followed worldwide. Each capsule contained 0.5 g of L1 white solid, with no preservatives or additives (see https://www.youtube.com/watch?v=ZcvSLyIgYd8, accessed on 1 March 2023).